Clinical Cancer Research, Vol 3, Issue 10 1807-1814, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma

MS Tsao, N Liu, T Nicklee, F Shepherd and J Viallet
Departments of Pathology, Ontario Cancer Institute/Princess Margaret Comprehensive Cancer Center-Toronto Hospital and University of Toronto, Ontario, M5G 2M9.

A total of 195 non-small cell lung carcinoma (NSCLC) specimens were studied for the presence of mutations in their ras family genes, for tumor vascularity, and for their immunostaining pattern with an antibody to vascular endothelial growth factor (VEGF). ras mutation was found in 37 of 104 (34.6%) adenocarcinoma specimens, in 0 of 64 squamous cell carcinomas, and in 2 of 27 (7.4%) large cell undifferentiated carcinomas. All mutations were found on the Ki-ras gene, with 37 (95%) of them on codon 12 and the remaining 2 on codon 13. Thirty (77%) of the mutations were G to T transversions. There was a correlation between increasing tumor vascularity and VEGF immunostaining score, but there was no correlation between either of them with the activation of the ras oncogene. A study of VEGF mRNA expression in 14 NSCLC cell lines also demonstrated a lack of correlation between the constitutive expression levels of VEGF and the presence or absence of ras mutation in these cell lines. The results suggest that VEGF is a major angiogenesis factor in NSCLC but that other factors beside ras mutations may influence tumor vascularity in these tumors. The two parameters may potentially serve as independent prognostic factors in NSCLC.

This article has been cited by other articles:

				M.-S. Tsao, S. Aviel-Ronen, K. Ding, D. Lau, N. Liu, A. Sakurada, M. Whitehead, C.-Q. Zhu, R. Livingston, D. H. Johnson, et al. Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non Small-Cell Lung Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5240 - 5247. [Abstract] [Full Text] [PDF]

				T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, C. Butts, Y. Cormier, G. Goss, R. Inculet, E. Vallieres, et al. Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer N. Engl. J. Med., June 23, 2005; 352(25): 2589 - 2597. [Abstract] [Full Text] [PDF]

				W Hilbe, S Dirnhofer, F Oberwasserlechner, T Schmid, E Gunsilius, G Hilbe, E Woll, and C M Kahler CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer J. Clin. Pathol., September 1, 2004; 57(9): 965 - 969. [Abstract] [Full Text] [PDF]

				C. Q. Zhu, F. H. Blackhall, M. Pintilie, P. Iyengar, N. Liu, J. Ho, T. Chomiak, D. Lau, T. Winton, F. A. Shepherd, et al. Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker Clin. Cancer Res., March 15, 2004; 10(6): 1984 - 1991. [Abstract] [Full Text] [PDF]

				G. H. Fisher, S. L. Wellen, D. Klimstra, J. M. Lenczowski, J. W. Tichelaar, M. J. Lizak, J. A. Whitsett, A. Koretsky, and H. E. Varmus Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes Genes & Dev., December 15, 2001; 15(24): 3249 - 3262. [Abstract] [Full Text] [PDF]

				F. Tanaka, Y. Otake, K. Yanagihara, Y. Kawano, R. Miyahara, M. Li, T. Yamada, N. Hanaoka, K. Inui, and H. Wada Evaluation of Angiogenesis in Non-small Cell Lung Cancer: Comparison between Anti-CD34 Antibody and Anti-CD105 Antibody Clin. Cancer Res., November 1, 2001; 7(11): 3410 - 3415. [Abstract] [Full Text] [PDF]

				M. Michael, B. Babic, R. Khokha, M. Tsao, J. Ho, M. Pintilie, K. Leco, D. Chamberlain, and F. A. Shepherd Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer J. Clin. Oncol., June 1, 1999; 17(6): 1802 - 1802. [Abstract] [Full Text] [PDF]